QC

Biogen pharmaceutical co’s services continue to care from prevention and cure. Biogen pharmaceutical co is devoted to the Innovation, manufacture, co-market and export of Pharmaceuticals and hospital products for Human. Biogen pharmaceutical co will ensures its presence in Indian markets for its products and services to companies with marketing alliance. Biogen pharmaceutical co today, has a strong reputation in marketing to the healthcare solutions.

Aalidhra Pharmachem is an (ISO 9001, 14001, OHSAS 18001 and Schedule M certified) Pharmaceutical Intermediates AND API manufacturing company established in 2015. We are working very closely with our customers to develop API opportunities to provide alternative, more economical, second-source options for existing generic drugs. By leveraging our worldwide sourcing, regulatory and quality assurance capabilities, we provide to generic drug manufacturers an alternative, economical source for existing API products. We, at Aalidhra Pharmachem Pvt. Ltd.

The 11th Annual Clinical Trials Summit 2020 to be held in Mumbai, India during 28th May 2020. The global Contract Research Organization (CRO) market size was estimated at US$ 34.5 billion in 2018 and is projected to reach US$ 55.3 billion by 2024, growing at a CAGR of 8.2% during 2019 to 2024. Indian clinical trials market size is expected to reach US$ 3.15 billion by 2025. It is projected to register a CAGR of 8.7% over the forecast period.Increasing cost of drug development is expected to drive the growth. Drug maker and sponsor companies are under pressure to replace the revenue loss caused by generics, increasing patent expiry, number of partnerships to identify biologics, and growing R&D costs, which has made drug development more expensive and complex. In addition, growing pressure on market players to follow stringent timelines has increased the demand for outsourcing of research activities.This Conference brings together Researchers, Doctors, Principle Investigators, Clinical research sites, CROs, CMOs, Investors, and senior executives from Biopharma, Medical devices and Pharmaceutical industries around the globe to discuss, reflect on and develop their ideas.

Ami Lifesciences was founded with the goal of changing the way in which quality medicines are delivered to people in need. We operate on the principle by extending our focus and services to maximize our impact on the global pharmaceutical industry  We have spent last two decades in building up our scientific and technological capabilities, research, and manufacturing competencies. Along the way we have earned a reputation for being innovative, inventive and resourceful. We have built long term business association pharmaceutical companies of the world.

Amnean Therapeutics is an innovative pharmaceutical company that develops and manufactures novel drug delivery systems for human application that are intended for both Indian, semi regulated and further to market in regulated biopharmaceutical markets.

Post : Senior QC Analyst

Mankind Pharma, the 7^th largest Pharmaceutical Company of India, was incepted in 1995 with a meagre capital of 50 lakhs and 20 employees. Today, we are amongst the top 5 fastest growing Pharmaceutical companies of India with an employee base of more than 10000 and heading towards a turnover of  INR 3000 crores.

The National Institute for Research in Tuberculosis [Formerly Tuberculosis Research Centre (TRC)], a permanent institute under the Indian Council of Medical Research (ICMR), is an internationally recognized institution for Tuberculosis (TB) research. It is a Supranational Reference Laboratory and a WHO Collaborating Centre for TB Research and Training. Recently, an International Centre for Excellence in Research (ICER) in collaboration with NIH was established at the Centre.

USA, a subsidiary of Revlon. Our product offering today includes Active Pharmaceutical Ingredients (APIs), Fixed Dosages Formulations (FDF), Peptides, Biosimilars and Injectables. These are manufactured in our cGMP compliant plants located in India.  We market our products globally to 65 countries. In the financial year 2018-19, our total income was Rs 31,065 million. Our Indian business contributed 83% to the revenue and the rest was from export of APIs and Finished Dosages.

Glenmark is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity) with eight molecules in various stages of clinical development. The company has a significant presence in branded generics markets across emerging economies including India. Its subsidiary, Glenmark Generics Limited has a fast growing and robust US generics business.